Research  |  Core Facilities  |  Patient Studies  |  Tech Transfer  |  Seminars  |  Intranet  |  Jobs  |  Search  |  Contact Us  |  Ways To Give                             HOME

What is OMRF?

Our History

Our Values

OMRF Leadership

Board of Directors

Disease Research

The Economic Impact
of OMRF

Breakthroughs at OMRF spell the difference between life and death.

Jeanne Morgan works in a hospital, is married to a physician and, as a clinical psychologist, understands how the human mind and body work. But the tired feeling that kept her at home one weekend was much more sinister than a simple cold or flu. Within hours, Morgan's vital organs began to shut down.

Unbeknownst to her, she had severe sepsis, a life-threatening blood infection. Fortunately, she recovered after doctors gave her Xigris, a drug that has its roots in the OMRF labs of Drs. Charles Esmon and Fletcher Taylor.

Xigris is the only FDA-approved treatment for a deadly illness that claims more than half a million lives each year, but it is not the only groundbreaking medication born at OMRF. There's also Ceprotin, the only biologic treatment for children born with a life-threatening protein C deficiency. And Soliris, the first drug to treat a rare and potentially deadly blood disorder known as PNH, likewise took shape in OMRF's labs. Our scientists also played a crucial role in developing drugs that stop the AIDS virus from replicating.

"If we didn't have breakthroughs like those taking place at OMRF, I wouldn't be here today," says Morgan. "You're saving lives."